{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bowman P"],"funding":["NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","Diabetes UK","National Institute for Health Research (NIHR)","Wellcome Trust","Novo Nordisk Fonden"],"pagination":["35-42"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7783935"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(1)"],"pubmed_abstract":["<h4>Objective</h4><i>ABCC8</i> mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with <i>ABCC8-</i>PNDM require lower sulfonylurea doses and have milder neurological features than those with <i>KCNJ11-</i>PNDM. However, these studies were short-term and included combinations of <i>ABCC8</i>-PNDM and <i>ABCC8</i>-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated <i>ABCC8</i>-PNDM.<h4>Research design and methods</h4>We studied all 24 individuals with <i>ABCC8-</i>PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before Ma"],"journal":["Diabetes care"],"pubmed_title":["Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated &lt;i&gt;ABCC8&lt;/i&gt; Permanent Neonatal Diabetes."],"pmcid":["PMC7783935"],"funding_grant_id":["R01-DK-104942","NF-SI-0611-10219","19/005971","16/0005407","PDA/02/06/098","NIHR4-SNMRL058","091985","105636/Z/14/Z","R01 DK104942","P30 DK020595","19/0005971","P30-DK-020595","098395/Z/12/Z","NNF18OC0054741","105636"],"pubmed_authors":["Greeley KW","Neonatal Diabetes International Collaborative Group","Russo L","Ford T","Sanchez J","Codner E","Kumaraguru Pillai J","Darendeliler F","Werner A","Chakera A","LeGault L","Dankovcikova A","Barbetti F","Stanik J","Rawlins E","Beltrand J","Njolstad P","Letourneau-Freiberg LR","Amratlal Patel K","Aydin B","Hattersley AT","Voorhoeve P","Sanchez JC","Cummings E","Finn R","Jain V","Bowman P","Babiker T","Bauer KE","Gallardo V","Mathews F","Ellard S","Raceala-Motoc S","Schebek M","Mohsin F","Greeley SAW","Bas F","Heffernan E","Shepherd MH","Sulen A","Piccini B","Rafiq M","Houghton J","Raile K","Iovane B","De Galan B","De Franco E","Bundak R","Flanagan SE","Thomas NJ","Polak M","Punthakee Z","Van Der Meulen J","Gasperikova D"],"additional_accession":[]},"is_claimable":false,"name":"Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated &lt;i&gt;ABCC8&lt;/i&gt; Permanent Neonatal Diabetes.","description":"<h4>Objective</h4><i>ABCC8</i> mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with <i>ABCC8-</i>PNDM require lower sulfonylurea doses and have milder neurological features than those with <i>KCNJ11-</i>PNDM. However, these studies were short-term and included combinations of <i>ABCC8</i>-PNDM and <i>ABCC8</i>-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated <i>ABCC8</i>-PNDM.<h4>Research design and methods</h4>We studied all 24 individuals with <i>ABCC8-</i>PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before Ma","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2026-06-06T22:48:57.528Z","creation":"2026-06-06T03:11:06.859Z"},"accession":"S-EPMC7783935","cross_references":{"pubmed":["33184150"],"doi":["10.2337/dc20-1520"]}}